The ban on “pay to delay” pharma patent settlements: shaving health care costs, fighting anti-competition, and patents — all rolled up into one

more+
less-

2 July 2010 – The U.S. House of Representatives has passed a measure banning patent settlements struck between brand-name and generic pharmaceutical companies to delay the release of generic drugs. The goal? To shave nearly $2 billion off government spending over the next decade. The measure was tacked onto the Iraq and Afghanistan war funding bill.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Gregory P. Bufithis, Esq., Project Counsel SCS | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.
×
Loading...
×